Roflumilast Foam 0.3% Secures Major FDA Approval to Treat Seborrheic Dermatitis
December 18th 2023The foam formulation and once-daily application of roflumilast foam 0.3%, the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades, makes it a favorable alternative to existing treatments.